Preparation and in vivo evaluation of nanoliposomes containing vancomycin after intravitreal injection in albino rabbits

The efficacy of nanoliposomal formulation of vancomycin against methicillin-resistant (MRSA) assessed. Nanoliposomal formulations were prepared and characterized. The study was carried out on rabbits which received liquid culture medium containing MRSA under anesthesia. After 48 hr, the eyes treated...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of basic medical sciences 2020-04, Vol.23 (4), p.551-555
Main Authors: Abrishami, Majid, Motamed Shariati, Mehrdad, Malaekeh-Nikouei, Bizhan, Tajani, Amineh Sadat, Mahmoudi, Asma, Abrishami, Mojtaba, Khameneh, Bahman
Format: Article
Language:English
Subjects:
Albinism
Antibiotics
Bacteria
drug delivery
Drugs
endophthalmitis
Gram-positive bacteria
Ions
Medical research
mrsa
nanopliposomes
Nanotechnology
Pharmaceutical industry
Pharmacy
Research centers
Short Communication
Staphylococcus infections
Studies
vancomycin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of nanoliposomal formulation of vancomycin against methicillin-resistant (MRSA) assessed. Nanoliposomal formulations were prepared and characterized. The study was carried out on rabbits which received liquid culture medium containing MRSA under anesthesia. After 48 hr, the eyes treated with the liposomal and free form of vancomycin. The rabbits were euthanized at predesignate intervals at 12, 24, 48, 96, 144 hr intervals injection. The antibacterial activity of different vancomycin formulations was assayed by the time killing method. The zeta potential, mean sizes and encapsulation efficacy of liposomal vancomycin were 29.7 mV, 381.93±30.13 nm and 47%, respectively. The results of time-killing studies indicated that the liposomal formula was more effective than the free form of vancomycin. The results of this study revealed that liposomal vancomycin formulation is a powerful nano-antibacterial agent to combat infectious endophthalmitis.
ISSN:2008-3866
2008-3874
DOI:10.22038/ijbms.2020.43447.10205